1190 related articles for article (PubMed ID: 11441939)
1. A systematic overview of chemotherapy effects in non-small cell lung cancer.
Sörenson S; Glimelius B; Nygren P;
Acta Oncol; 2001; 40(2-3):327-39. PubMed ID: 11441939
[TBL] [Abstract][Full Text] [Related]
2. A systematic overview of chemotherapy effects in ovarian cancer.
Högberg T; Glimelius B; Nygren P;
Acta Oncol; 2001; 40(2-3):340-60. PubMed ID: 11441940
[TBL] [Abstract][Full Text] [Related]
3. A systematic overview of chemotherapy effects in colorectal cancer.
Ragnhammar P; Hafström L; Nygren P; Glimelius B;
Acta Oncol; 2001; 40(2-3):282-308. PubMed ID: 11441937
[TBL] [Abstract][Full Text] [Related]
4. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.
Clegg A; Scott DA; Sidhu M; Hewitson P; Waugh N
Health Technol Assess; 2001; 5(32):1-195. PubMed ID: 12065068
[TBL] [Abstract][Full Text] [Related]
5. A systematic overview of chemotherapy effects in breast cancer.
Bergh J; Jönsson PE; Glimelius B; Nygren P;
Acta Oncol; 2001; 40(2-3):253-81. PubMed ID: 11441936
[TBL] [Abstract][Full Text] [Related]
6. Taxanes as first-line therapy for advanced non-small cell lung cancer: a systematic review and practice guideline.
Chu Q; Vincent M; Logan D; Mackay JA; Evans WK;
Lung Cancer; 2005 Dec; 50(3):355-74. PubMed ID: 16139391
[TBL] [Abstract][Full Text] [Related]
7. [Treatment of the unresectable non small cell lung carcinoma].
Spásová I
Cas Lek Cesk; 2005; 144(9):602-12; discussion 612-3. PubMed ID: 16193938
[TBL] [Abstract][Full Text] [Related]
8. A systematic overview of chemotherapy effects in gastric cancer.
Janunger KG; Hafström L; Nygren P; Glimelius B;
Acta Oncol; 2001; 40(2-3):309-26. PubMed ID: 11441938
[TBL] [Abstract][Full Text] [Related]
9. Adjuvant chemotherapy for resected early-stage non-small cell lung cancer.
Burdett S; Pignon JP; Tierney J; Tribodet H; Stewart L; Le Pechoux C; Aupérin A; Le Chevalier T; Stephens RJ; Arriagada R; Higgins JP; Johnson DH; Van Meerbeeck J; Parmar MK; Souhami RL; Bergman B; Douillard JY; Dunant A; Endo C; Girling D; Kato H; Keller SM; Kimura H; Knuuttila A; Kodama K; Komaki R; Kris MG; Lad T; Mineo T; Piantadosi S; Rosell R; Scagliotti G; Seymour LK; Shepherd FA; Sylvester R; Tada H; Tanaka F; Torri V; Waller D; Liang Y;
Cochrane Database Syst Rev; 2015 Mar; 2015(3):CD011430. PubMed ID: 25730344
[TBL] [Abstract][Full Text] [Related]
10. A systematic overview of radiation therapy effects in non-small cell lung cancer.
Sirzén F; Kjellén E; Sörenson S; Cavallin-Ståhl E
Acta Oncol; 2003; 42(5-6):493-515. PubMed ID: 14596509
[TBL] [Abstract][Full Text] [Related]
11. Unresected stage III non-small-cell lung cancer. Provincial Lung Cancer Disease Site Group.
Okawara G; Rusthoven J; Newman T; Findlay B; Evans W
Cancer Prev Control; 1997 Aug; 1(3):249-59. PubMed ID: 9765750
[TBL] [Abstract][Full Text] [Related]
12. Paclitaxel: a pharmacoeconomic review of its use in non-small cell lung cancer.
Plosker GL; Hurst M
Pharmacoeconomics; 2001; 19(11):1111-34. PubMed ID: 11735678
[TBL] [Abstract][Full Text] [Related]
13. A systematic overview of chemotherapy effects in urothelial bladder cancer.
Nilsson S; Ragnhammar P; Glimelius B; Nygren P;
Acta Oncol; 2001; 40(2-3):371-90. PubMed ID: 11441942
[TBL] [Abstract][Full Text] [Related]
14. Paclitaxel-based therapy in non-small-cell lung cancer: improved third generation chemotherapy.
Greco FA; Hainsworth JD
Ann Oncol; 1999; 10 Suppl 5():S63-7. PubMed ID: 10582142
[TBL] [Abstract][Full Text] [Related]
15. Cisplatin/carboplatin + etoposide + vinorelbine in advanced non-small-cell lung cancer: a multicentre randomised trial. Gruppo Oncologico Campano.
Comella P; Frasci G; De Cataldis G; Panza N; Cioffi R; Curcio C; Belli M; Bianco A; Ianniello G; Maiorino L; Della Vittoria M; Perchard J; Comella G
Br J Cancer; 1996 Dec; 74(11):1805-11. PubMed ID: 8956797
[TBL] [Abstract][Full Text] [Related]
16. Radiotherapy and chemotherapy in locally advanced non-small cell lung cancer: preclinical and early clinical data.
Reboul FL
Hematol Oncol Clin North Am; 2004 Feb; 18(1):41-53. PubMed ID: 15005280
[TBL] [Abstract][Full Text] [Related]
17. Medical therapy of advanced malignant epithelial tumours of the ovary.
Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A
Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983
[TBL] [Abstract][Full Text] [Related]
18. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial.
Paz-Ares L; de Marinis F; Dediu M; Thomas M; Pujol JL; Bidoli P; Molinier O; Sahoo TP; Laack E; Reck M; Corral J; Melemed S; John W; Chouaki N; Zimmermann AH; Visseren-Grul C; Gridelli C
Lancet Oncol; 2012 Mar; 13(3):247-55. PubMed ID: 22341744
[TBL] [Abstract][Full Text] [Related]
19. Chemotherapy for patients with non-small cell lung cancer: the surgical setting of the Big Lung Trial.
Waller D; Peake MD; Stephens RJ; Gower NH; Milroy R; Parmar MK; Rudd RM; Spiro SG
Eur J Cardiothorac Surg; 2004 Jul; 26(1):173-82. PubMed ID: 15200998
[TBL] [Abstract][Full Text] [Related]
20. Docetaxel for locally advanced or metastatic non-small-cell lung cancer. Current data and future directions as front-line therapy.
Khuri FR
Oncology (Williston Park); 2002 Jun; 16(6 Suppl 6):53-62. PubMed ID: 12108898
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
